| An integrated population pharmacokinetic model was developed and externally validated for both remdesivir and GS-441524 in patients hospitalized with COVID-19. |
| The concentration of GS-441524 was substantially higher in patients with reduced kidney function due to decreased clearance. |
| The concentration of GS-441524 was substantially higher in patients with older age due to a smaller volume of distribution. |
| This model can guide dosing of remdesivir in patients of varying ages and health. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.